

HR 6574

Medicare Fair Drug Pricing Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 26, 2018

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Aug 13, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/6574>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 27, 2018
Ways and Means Committee	House	Referred to	Aug 13, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Medicare Fair Drug Pricing Act of 2018

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.

Under current law, the CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. The CMS must promulgate regulations regarding the identification of such drugs.

With respect to these drugs, the CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.

A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.

Actions Timeline

- **Aug 13, 2018:** Referred to the Subcommittee on Health.
- **Jul 27, 2018:** Referred to the Subcommittee on Health.
- **Jul 26, 2018:** Introduced in House
- **Jul 26, 2018:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.